Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats

Brain Research Bulletin

Volumn 113, Issue , 2015, Pages 1-7

  Citraro, Rita ^a   Leo, Antonio ^a   Marra, Rosario ^b   De Sarro, Giovambattista ^a   Russo, Emilio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

Author keywords

Absence epileptogenesis; Cyclooxygenase (COX); Etoricoxib; Neuroinflammation; Spike wave discharges (SWDs); WAG Rij rats

Indexed keywords

ANTICONVULSIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; CYCLOOXYGENASE 2; PTGS2 PROTEIN, RAT; PYRIDINE DERIVATIVE; SULFONE;

ABSENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG MECHANISM; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPIKE WAVE; WISTAR ALBINO GLAXO RAT; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; ENZYMOLOGY; EPILEPSY, ABSENCE; FEMALE; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PROCEDURES; WISTAR RAT;

ANIMALS; ANTICONVULSANTS; BRAIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; FEMALE; MALE; MOTOR ACTIVITY; PYRIDINES; RATS; RATS, WISTAR; SULFONES;

EID: 84923374742     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2015.02.004     Document Type: Article

References (88)

1. Adams J., Collaco-Moraes Y., de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J. Neurochem. 1996, 66:6-13.
2. Aid S., Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011, 93:46-51. 10.1016/j.biochi.2010.09.009.
3. Akin D., Ravizza T., Maroso M., Carcak N., Eryigit T., Vanzulli I., Aker R.G., Vezzani A., Onat F.Y. IL-1beta is induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence. Neurobiol. Dis. 2011, 44:259-269. 10.1016/j.nbd.2011.05.015.
4. Akula K.K., Dhir A., Kulkarni S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Res. 2008, 78:60-70. 10.1016/j.eplepsyres.2007.10.008.
5. Baik E.J., Kim E.J., Lee S.H., Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999, 843:118-129.
6. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., Pozzan T., Volterra A. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998, 391:281-285. 10.1038/34651.
7. Blumenfeld H., Klein J.P., Schridde U., Vestal M., Rice T., Khera D.S., Bashyal C., Giblin K., Paul-Laughinghouse C., Wang F., Phadke A., Mission J., Agarwal R.K., Englot D.J., Motelow J., Nersesyan H., Waxman S.G., Levin A.R. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008, 49:400-409. 10.1111/j.1528-1167.2007.01458.x.
8. 2+ spike in the thalamus of a rat model of absence epilepsy. Mol. Cell Neurosci. 2008, 39:384-399. 10.1016/j.mcn.2008.07.012.
9. Choi J., Koh S. Role of brain inflammation in epileptogenesis. Yonsei Med. J. 2008, 49:1-18. 10.3349/ymj.2008.49.1.1.
10. Ciceri P., Zhang Y., Shaffer A.F., Leahy K.M., Woerner M.B., Smith W.G., Seibert K., Isakson P.C. Pharmacology of celecoxib in rat brain after kainate administration. J. Pharmacol. Exp. Ther. 2002, 302:846-852.
11. Citraro R., Chimirri S., Aiello R., Gallelli L., Trimboli F., Britti D., De Sarro G., Russo E. Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 2014, 55:1284-1291. 10.1111/Epi.12686.
12. Citraro R., Russo E., Di Paola E.D., Ibbadu G.F., Gratteri S., Marra R., De Sarro G. Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006, 50:1059-1071. 10.1016/j.neuropharm.2006.02.011.
13. Citraro R., Russo E., Gratteri S., Di Paola E.D., Ibbadu G.F., Curinga C., Gitto R., Chimirri A., Donato G., De Sarro G. Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006, 51:1058-1067. 10.1016/j.neuropharm.2006.06.014.
14. Citraro R., Russo E., Ngomba R.T., Nicoletti F., Scicchitano F., Whalley B.J., Calignano A., De Sarro G. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res. 2013, 106:74-82. 10.1016/j.eplepsyres.2013.06.004.
15. Citraro R., Russo E., Scicchitano F., van Rijn C.M., Cosco D., Avagliano C., Russo R., D'Agostino G., Petrosino S., Guida F., Gatta L., van Luijtelaar G., Maione S., Di Marzo V., Calignano A., De Sarro G. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-alpha receptor activation in a genetic model of absence epilepsy. Neuropharmacology 2013, 69:115-126. 10.1016/j.neuropharm.2012.11.017.
16. Coenen A.M., Drinkenburg W.H., Inoue M., van Luijtelaar E.L. Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats. Epilepsy Res. 1992, 12:75-86.
17. Desjardins P., Sauvageau A., Bouthillier A., Navarro D., Hazell A.S., Rose C., Butterworth R.F. Induction of astrocytic cyclooxygenase-2 in epileptic patients with hippocampal sclerosis. Neurochem. Int. 2003, 42:299-303.
18. Dezsi G., Ozturk E., Stanic D., Powell K.L., Blumenfeld H., O'Brien T.J., Jones N.C. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. Epilepsia 2013, 54:635-643. 10.1111/epi.12118.
19. Dhir A., Naidu P.S., Kulkarni S.K. Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models (bicuculline, picrotoxin, maximal electroshock-induced convulsions) of epilepsy with possible mechanism of action. Indian J. Exp. Biol. 2006, 44:286-291.
20. Dhir A., Naidu P.S., Kulkarni S.K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 2007, 16:691-697. 10.1016/j.seizure.2007.05.016.
21. Dhir A., Padi S.S., Naidu P.S., Kulkarni S.K. Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice. Eur. J. Pharmacol. 2006, 535:192-198. 10.1016/j.ejphar.2006.01.064.
22. Ehling P., Cerina M., Meuth P., Kanyshkova T., Bista P., Coulon P., Meuth S.G., Pape H.C., Budde T. Ca(2+)-dependent large conductance K(+) currents in thalamocortical relay neurons of different rat strains. Pflugers Arch. 2012, 10.1007/s00424-012-1188-6.
23. Giblin K.A., Blumenfeld H. Is epilepsy a preventable disorder? New evidence from animal models. Neuroscientist 2010, 16:253-275. 10.1177/1073858409354385.
24. Gyorffy B., Kovacs Z., Gulyassy P., Simor A., Volgyi K., Orban G., Baracskay P., Szabo Z., Janaky T., Dobolyi A., Juhasz G., Czurko A., Kekesi K.A. Brain protein expression changes in WAG/Rij rats, a genetic rat model of absence epilepsy after peripheral lipopolysaccharide treatment. Brain Behav. Immun. 2014, 35:86-95. 10.1016/j.bbi.2013.09.001.
25. Holtman L., van Vliet E.A., van Schaik R., Queiroz C.M., Aronica E., Gorter J.A. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res. 2009, 84:56-66. 10.1016/j.eplepsyres.2008.12.006.
26. Jayaraman R., Manisenthil K.T., Anitha T., Joshi V.D., Palei N.N., Gajera K., Ladani K. Influence of etoricoxib on anticonvulsant activity of phenytoin and diazepam in experimental seizure models in mice. J. Pharm. Pharmacol. 2010, 62:610-614. 10.1211/jpp/62.05.0008.
27. Jung K.H., Chu K., Lee S.T., Kim J., Sinn D.I., Kim J.M., Park D.K., Lee J.J., Kim S.U., Kim M., Lee S.K., Roh J.K. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 2006, 23:237-246. 10.1016/j.nbd.2006.02.016.
28. Kanyshkova T., Meuth P., Bista P., Liu Z., Ehling P., Caputi L., Doengi M., Chetkovich D.M., Pape H.C., Budde T. Differential regulation of HCN channel isoform expression in thalamic neurons of epileptic and non-epileptic rat strains. Neurobiol. Dis. 2012, 45:450-461. 10.1016/j.nbd.2011.08.032.
29. Kawaguchi K., Hickey R.W., Rose M.E., Zhu L., Chen J., Graham S.H. Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus. Brain Res. 2005, 1050:130-137. 10.1016/j.brainres.2005.05.038.
30. Kim E.J., Lee J.E., Kwon K.J., Lee S.H., Moon C.H., Baik E.J. Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandin E(2) production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res. 2001, 908:1-9.
31. Kim H.J., Chung J.I., Lee S.H., Jung Y.S., Moon C.H., Baik E.J. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res. 2008, 1193:153-161. 10.1016/j.brainres.2007.12.017.
32. Kim S.Y., Buckwalter M., Soreq H., Vezzani A., Kaufer D. Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis. Epilepsia 2012, 53(Suppl. 6):37-44. 10.1111/j.1528-1167.2012.03701.x.
33. Kole M.H., Brauer A.U., Stuart G.J. Inherited cortical HCN1 channel loss amplifies dendritic calcium electrogenesis and burst firing in a rat absence epilepsy model. J. Physiol. 2007, 578:507-525. 10.1113/jphysiol.2006.122028.
34. Kovacs Z., Czurko A., Kekesi K.A., Juhasz G. Intracerebroventricularly administered lipopolysaccharide enhances spike-wave discharges in freely moving WAG/Rij rats. Brain Res. Bull. 2011, 85:410-416. 10.1016/j.brainresbull.2011.05.003.
35. Kovacs Z., Dobolyi A., Juhasz G., Kekesi K.A. Lipopolysaccharide induced increase in seizure activity in two animal models of absence epilepsy WAG/Rij and GAERS rats and Long Evans rats. Brain Res. Bull. 2014, 104:7-18. 10.1016/j.brainresbull.2014.03.003.
36. Kulkarni S.K., Dhir A. Cyclooxygenase in epilepsy: from perception to application. Drugs Today (Barc) 2009, 45:135-154. 10.1358/dot.2009.45.2.1322481.
37. Kunz T., Oliw E.H. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur. J. Neurosci. 2001, 13:569-575.
38. Liu J.Y., Thom M., Catarino C.B., Martinian L., Figarella-Branger D., Bartolomei F., Koepp M., Sisodiya S.M. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012, 135:3115-3133. 10.1093/brain/aws147.
39. Liu X.B., Coble J., van Luijtelaar G., Jones E.G. Reticular nucleus-specific changes in alpha3 subunit protein at GABA synapses in genetically epilepsy-prone rats. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12512-12517. 10.1073/pnas.0705320104.
40. Marchi N., Granata T., Janigro D. Inflammatory pathways of seizure disorders. Trends Neurosci. 2014, 37:55-65. 10.1016/j.tins.2013.11.002.
41. Meeren H., van Luijtelaar G., Lopes da Silva F., Coenen A. Evolving concepts on the pathophysiology of absence seizures: the cortical focus theory. Arch. Neurol. 2005, 62:371-376. 10.1001/archneur.62.3.371.
42. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 2004, 63:901-910.
43. Ngomba R.T., Ferraguti F., Badura A., Citraro R., Santolini I., Battaglia G., Bruno V., De Sarro G., Simonyi A., van Luijtelaar G., Nicoletti F. Positive allosteric modulation of metabotropic glutamate 4 (mGlu4) receptors enhances spontaneous and evoked absence seizures. Neuropharmacology 2008, 54:344-354. 10.1016/j.neuropharm.2007.10.004.
44. Okada K., Yuhi T., Tsuji S., Yamashita U. Cyclooxygenase-2 expression in the hippocampus of genetically epilepsy susceptible El mice was increased after seizure. Brain Res. 2001, 894:332-335.
45. Peeters B.W., Ramakers G.M., Ellenbroek B.A., Vossen J.M., Coenen A.M. Interactions between NMDA and nonNMDA receptors in nonconvulsive epilepsy in the WAG/Rij inbred strain. Brain Res. Bull. 1994, 33:715-718.
46. Perrone M.G., Scilimati A., Simone L., Vitale P. Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr. Med. Chem. 2010, 17:3769-3805.
47. Pisu M.G., Mostallino M.C., Dore R., Mura M.L., Maciocco E., Russo E., De Sarro G., Serra M. Neuroactive steroids and GABAA receptor plasticity in the brain of the WAG/Rij rat, a model of absence epilepsy. J. Neurochem. 2008, 106:2502-2514. 10.1111/j.1471-4159.2008.05538.x.
48. Pitkanen A., Engel J. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics 2014, 11:231-241. 10.1007/s13311-014-0257-2.
49. Polascheck N., Bankstahl M., Loscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp. Neurol. 2010, 224:219-233. 10.1016/j.expneurol.2010.03.014.
50. Quan Y., Jiang J., Dingledine R. EP2 receptor signaling pathways regulate classical activation of microglia. J. Biol. Chem. 2013, 288:9293-9302. 10.1074/jbc.M113.455816.
51. Rimoli M.G., Russo E., Cataldi M., Citraro R., Ambrosino P., Melisi D., Curcio A., De Lucia S., Patrignani P., De Sarro G., Abignente E. T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. Neuropharmacology 2009, 56:637-646. 10.1016/j.neuropharm.2008.11.003.
52. Rojas A., Jiang J., Ganesh T., Yang M.S., Lelutiu N., Gueorguieva P., Dingledine R. Cyclooxygenase-2 in epilepsy. Epilepsia 2014, 55:17-25. 10.1111/epi.12461.
53. Russo E., Andreozzi F., Iuliano R., Dattilo V., Procopio T., Fiume G., Mimmi S., Perrotti N., Citraro R., Sesti G., Constanti A., De Sarro G. Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release. Brain Behav. Immun. 2014, 42:157-168. 10.1016/j.bbi.2014.06.016.
54. Russo E., Citraro R., De Fazio S., Marra R., Gitto R., Chimirri A., De Sarro G., Di Paola E.D. Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy. Epilepsy Behav. 2008, 13:295-299. 10.1016/j.yebeh.2008.04.018.
55. Russo E., Citraro R., Donato G., Camastra C., Iuliano R., Cuzzocrea S., Constanti A., De Sarro G. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2013, 69:25-36. 10.1016/j.neuropharm.2012.09.019.
56. Russo E., Citraro R., Scicchitano F., Urzino A., Marra R., Rispoli V., De Sarro G. Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav. Brain Res. 2011, 225:373-376. 10.1016/j.bbr.2011.07.030.
57. Russo E., Follesa P., Citraro R., Camastra C., Donato A., Isola D., Constanti A., De Sarro G., Donato G. The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model. Neurol. Sci. 2014, 35:1793-1799. 10.1007/s10072-014-1842-1.
58. Sayyah M., Javad-Pour M., Ghazi-Khansari M. The bacterial endotoxin lipopolysaccharide enhances seizure susceptibility in mice: involvement of proinflammatory factors: nitric oxide and prostaglandins. Neuroscience 2003, 122:1073-1080.
59. Schridde U., van Luijtelaar G. Corticosterone increases spike-wave discharges in a dose- and time-dependent manner in WAG/Rij rats. Pharmacol. Biochem. Behav. 2004, 78:369-375. 10.1016/j.pbb.2004.04.012.
60. Serrano G.E., Lelutiu N., Rojas A., Cochi S., Shaw R., Makinson C.D., Wang D., FitzGerald G.A., Dingledine R. Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J. Neurosci. 2011, 31:14850-14860. 10.1523/JNEUROSCI.3922-11.2011.
61. Shafiq N., Malhotra S., Pandhi P. Anticonvulsant action of celecoxib (alone and in combination with sub-threshold dose of phenytoin) in electroshock induced convulsion. Methods Find. Exp. Clin. Pharmacol. 2003, 25:87-90.
62. Shimada T., Takemiya T., Sugiura H., Yamagata K. Role of inflammatory mediators in the pathogenesis of epilepsy. Mediators Inflamm. 2014, 2014:901902. 10.1155/2014/901902.
63. Sitnikova E. Thalamo-cortical mechanisms of sleep spindles and spike-wave discharges in rat model of absence epilepsy (a review). Epilepsy Res. 2010, 89:17-26. 10.1016/j.eplepsyres.2009.09.005.
64. Strauss K.I. Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav. Immun. 2008, 22:285-298. 10.1016/j.bbi.2007.09.011.
65. Takacs E., Nyilas R., Szepesi Z., Baracskay P., Karlsen B., Rosvold T., Bjorkum A.A., Czurko A., Kovacs Z., Kekesi A.K., Juhasz G. Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity. Neurochem. Int. 2010, 56:799-809. 10.1016/j.neuint.2010.03.003.
66. Takemiya T., Maehara M., Matsumura K., Yasuda S., Sugiura H., Yamagata K. Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci. Res. 2006, 56:103-110. 10.1016/j.neures.2006.06.003.
67. Takemiya T., Suzuki K., Sugiura H., Yasuda S., Yamagata K., Kawakami Y., Maru E. Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling. Prostaglandins Other Lipid Mediat. 2003, 71:205-216.
68. 2+ channel alpha1G. J. Gen. Physiol. 2004, 124:225-238. 10.1085/jgp.200409050.
69. Tanaka S., Nakamura T., Sumitani K., Takahashi F., Konishi R., Itano T., Miyamoto O. Stage- and region-specific cyclooxygenase expression and effects of a selective COX-1 inhibitor in the mouse amygdala kindling model. Neurosci. Res. 2009, 65:79-87. 10.1016/j.neures.2009.05.013.
70. Tandon M., Anuradha K., Pandhi P. Evaluation of antiepileptic activity of aspirin in combination with newer antiepileptic lamotrigine in mice. Methods Find. Exp. Clin. Pharmacol. 2003, 25:607-610.
71. Toscano C.D., Kingsley P.J., Marnett L.J., Bosetti F. NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology 2008, 29:1114-1120. 10.1016/j.neuro.2008.08.008.
72. Tu B., Bazan N.G. Hippocampal kindling epileptogenesis upregulates neuronal cyclooxygenase-2 expression in neocortex. Exp. Neurol. 2003, 179:167-175.
73. van Luijtelaar G., Lyashenko S., Vastyanov R., Verbeek G., Oleinik A., Rijn C., Volokhova G., Shandra A., Coenen A., Godlevsky L. Cytokines and absence seizures in a genetic rat model. Neurophysiology 2012, 43:478-486. 10.1007/s11062-012-9252-6.
74. van Luijtelaar G., Onat F.Y., Gallagher M.J. Animal models of absence epilepsies: what do they model and do sex and sex hormones matter?. Neurobiol. Dis. 2014, 10.1016/j.nbd.2014.08.014.
75. van Luijtelaar G., Sitnikova E. Global and focal aspects of absence epilepsy: the contribution of genetic models. Neurosci. Biobehav. Rev. 2006, 30:983-1003. 10.1016/j.neubiorev.2006.03.002.
76. van Luijtelaar G., Sitnikova E., Littjohann A. On the origin and suddenness of absences in genetic absence models. Clin. EEG Neurosci. 2011, 42:83-97.
77. van Luijtelaar G., Wiaderna D., Elants C., Scheenen W. Opposite effects of T- and L-type Ca(2+) channels blockers in generalized absence epilepsy. Eur. J. Pharmacol. 2000, 406:381-389.
78. van Luijtelaar G., Zobeiri M. Progress and outlooks in a genetic absence epilepsy model (WAG/Rij). Curr. Med. Chem. 2014, 21:704-721.
79. Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr. 2014, 14:3-7. 10.5698/1535-7511-14.s2.3.
80. Vezzani A., Aronica E., Mazarati A., Pittman Q.J. Epilepsy and brain inflammation. Exp. Neurol. 2013, 244:11-21. 10.1016/j.expneurol.2011.09.033.
81. Vezzani A., Balosso S., Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav. Immun. 2008, 22:797-803. 10.1016/j.bbi.2008.03.009.
82. Vezzani A., Friedman A., Dingledine R.J. The role of inflammation in epileptogenesis. Neuropharmacology 2013, 69:16-24. 10.1016/j.neuropharm.2012.04.004.
83. Vezzani A., Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005, 46:1724-1743. 10.1111/j.1528-1167.2005.00298.x.
84. Voutsinos-Porche B., Koning E., Kaplan H., Ferrandon A., Guenounou M., Nehlig A., Motte J. Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy. Neurobiol. Dis. 2004, 17:385-402. 10.1016/j.nbd.2004.07.023.
85. White H.S., Loscher W. Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurotherapeutics 2014, 11:373-384. 10.1007/s13311-013-0250-1.
86. Wilcox K.S., Vezzani A. Does brain inflammation mediate pathological outcomes in epilepsy?. Adv. Exp. Med. Biol. 2014, 813:169-183. 10.1007/978-94-017-8914-1_14.
87. Xu D., Miller S.D., Koh S. Immune mechanisms in epileptogenesis. Front. Cell Neurosci. 2013, 7:195. 10.3389/fncel.2013.00195.
88. Zhang H.J., Sun R.P., Lei G.F., Yang L., Liu C.X. Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats. J. Zhejiang Univ. Sci. B 2008, 9:903-915. 10.1631/jzus.B0820018.